[ad_1]
License switch highlights Fujitsu’s open innovation method with Silicon Valley ecosystem to convey superior applied sciences to market to deal with social challenges
Fujitsu Limited, Delight Health
Tokyo and Palo Alto, CA November 20, 2023
Fujitsu Limited and Delight Health, a Bay Area startup, at the moment introduced that Fujitsu will license its Topological Data Analysis (TDA) know-how to Delight Health in trade for an fairness place within the firm. This license switch will assist Delight Health’s plans to achieve fast FDA approval by fiscal 2024 and convey to market a sophisticated delirium (1) detection gadget to precisely predict the onset of the dysfunction and deal with the wants of sufferers affected by this ailment.
Fujitsu developed TDA, an AI know-how that permits evaluation of abnormalities and disturbances in advanced, distorted and unstable time sequence knowledge with broad purposes in a spread of industries together with healthcare, manufacturing and infrastructure. From July 2018 to May 2021, Fujitsu researchers and Dr. Shinozaki at Stanford University (2) performed joint analysis on the applying of TDA to delirium detection utilizing electroencephalogram (EEG) knowledge. The distinctive end result of analysis was the flexibility to precisely detect delirium utilizing a conveyable single-channel EEG gadget with the bispectral EEG (BSEEG) algorithm (3) considerably enhanced by Fujitsu‘s TDA technology. The joint research resulted in several publications, including a research paper published in 2021 (4).
In July 2023, Dr. Shinozaki co-founded Delight Health (DH) as a new company to commercialize this award-winning technology (5). “Delight” was named after their vision to bring “light” to “delirium”. Fujitsu will grant Delight Health a license to use TDA and will take an equity position in the company.
“Leveraging advanced technologies to solve human and societal problems is core to Fujitsu’s mission and goal,” stated Hideto (Ted) Okada, SVP and Head of Technology Strategy Unit at Fujitsu. “By partnering with Delight Health to deliver innovative solutions to detect and treat neurological and psychiatric disorders, we hope to increase the health and wellbeing of millions of people around the world.”
“Fujitsu is a company recognized for its advanced technologies and research excellence and our joint collaboration has resulted in significant scientific breakthroughs,” stated Prof. Gen Shinozaki, co-founder of Delight Health. “By taking an equity position in Delight Health, Fujitsu is demonstrating its business commitment to accelerate the delivery of products to more effectively identify delirium paving the way for new therapies and better patient outcomes”.
Background and Challenges
Delirium is a critical dysfunction that impacts hundreds of thousands of individuals world wide. In the United States alone 2-3 million older grownup sufferers endure from delirium yearly. Delirium is estimated to end in a 40% mortality fee after one yr (6) and impression over $150B (7) to the healthcare system. Healthcare professionals present depend on questionnaires to seek out the dysfunction’s incidence, which stays topic to particular person interpretation by the busy hospital workers and might sometimes end in incorrect analysis and delayed intervention. AI primarily based prediction can drastically improve the accuracy and allow early detection and therapy, leading to important price financial savings and higher affected person outcomes.
1. Period:
November 2023 to November 2028
2. Responsibilities of the 2 firms:
Fujitsu
- Fujitsu will present TDA software program, coaching and technical assist to make sure DH engineers are in a position to achieve obligatory experience in TDA and have ample data to combine TDA into the delirium detection gadget being developed by Delight Health.
- Fujitsu may have the unique proper to co-market, promote, distribute and in any other case commercialize any licensed merchandise developed by Delight Health in Japan the place Fujitsu would be the prime supplier with respect to a buyer in Japan or buyer whose headquarter sits in Japan.
Delight Health
- Will combine TDA into their Delirium detection gadget.
- Will receive FDA approval wanted to supply Delirium measurement companies to suppliers.
- Will market and promote each the Delirium gadget, companies to assist and seize measurement revenues as soon as gadget is bought to hospitals and clinics.
Future Plans
Fujitsu plans to additional discover alternatives to ship superior applied sciences to progressive startups to hurry up options to social challenges.
Related Links
About Fujitsu
Fujitsu’s goal is to make the world extra sustainable by constructing belief in society by way of innovation. As the digital transformation companion of alternative for purchasers in over 100 international locations, our 124,000 workers work to resolve among the best challenges going through humanity. Our vary of companies and options draw on 5 key applied sciences: Computing, Networks, AI, Data & Security, and Converging Technologies, which we convey collectively to ship sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of three.7 trillion yen (US$28 billion) for the fiscal yr ended March 31, 2023 and stays the highest digital companies firm in Japan by market share. Find out extra: www.fujitsu.com.
About Delight Health
Led by Prof. Gen Shinozaki from Stanford University, Delight Health is innovating delirium care. Central to its groundbreaking method is a state-of-the-art confirmed EEG gadget and algorithm designed to detect and predict delirium by analyzing sufferers’ mind alerts. Beyond mere detection, this know-how will supply a proactive method to affected person care, making certain well timed interventions. In a delirium panorama the place precision is paramount, Delight Health’s EEG resolution will present promising accuracy, pace, and reliability in delirium care.
Press Contacts
Fujitsu Limited
Public and Investor Relations Division
Inquiries
All firm or product names talked about herein are emblems or registered emblems of their respective house owners. Information supplied on this press launch is correct at time of publication and is topic to vary with out advance discover.
Date: 20 November, 2023
City: Tokyo and Palo Alto, CA
Company: Fujitsu Limited, Delight Health
[adinserter block=”4″]
[ad_2]
Source link